Vanda Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company’s research efforts are concentrated on conditions related to sleep and neurological diseases, with several late-stage and approved products addressing unmet medical needs. Vanda’s portfolio and pipeline reflect its commitment to innovative drug development in areas where treatment options are limited and patient populations are underserved.
Among Vanda’s marketed products is Hetlioz (tasimelteon), a melatonin receptor agonist approved for the treatment of non-24-hour sleep-wake disorder in totally blind individuals. The company has also developed Fanapt (iloperidone), an atypical antipsychotic for schizophrenia, and Trudhesa (dihydroergotamine mesylate nasal spray) to address acute migraine attacks in adults. Vanda continues to advance its pipeline with investigational candidates targeting hepatic encephalopathy, dopamine-regulated disorders and other therapeutic areas within the CNS space.
Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates a global research and development infrastructure, with facilities in North America and Europe. The company leverages strategic partnerships and collaborations to enhance its clinical programs and streamline regulatory pathways. Vanda’s team engages in ongoing dialogue with regulatory agencies to support its late-stage trials and potential label expansions for existing products.
Under the leadership of President and Chief Executive Officer Mihael H. Polymeropoulos, Vanda maintains a scientific-driven approach, supported by an executive team with deep experience in neuroscience and drug commercialization. The company’s strategic priorities include advancing late-stage assets through pivotal studies, exploring new indications, and expanding its commercial footprint to better serve patients with CNS disorders worldwide.
AI Generated. May Contain Errors.